Search Videos and More

Showing 1 - 12 of 28 results

Previous| 1 | 2 | 3 |Next


SABCS 2022: Sara Tolaney, MD, MPH Video

SABCS 2022: Sara Tolaney, MD, MPH

Updated data from the APT trial shows that after 10 years of follow-up, adjuvant paclitaxel and trastuzumab confirm excellent long-term outcomes for small, node-negative HER2-positive breast cancer.
SABCS 2022: Paolo Tarantino, MD Video

SABCS 2022: Paolo Tarantino, MD

ATEMPT study shows that 5 years after treatment, 97% of patient's w/stage 1 HER2+ breast cancer treated w/TDM1 were alive and free from invasive disease and 98.3% had no recurrence of their cancer.
SABCS 2022: Ann Partridge, MD, MPH Video

SABCS 2022: Ann Partridge, MD, MPH

Ann Partridge, MD, MPH, led the study presented at the 2022 San Antonio Breast Cancer Symposium which showed most women participating in the study went on to deliver healthy babies.
SABCS 2022: Rachel Freedman, MD, MPH Video

SABCS 2022: Rachel Freedman, MD, MPH

Rachel Freedman, MD, MPH, shared results from the TBCRC 022 study where Neratinib in combination w/T-DM1 showed promising activity in patients w/heavily pre-treated HER2+ breast cancer metastatic to the central nervous system.
San Antonio Breast Cancer Symposium (SABCS): December 2022 Symposium

San Antonio Breast Cancer Symposium (SABCS): December 2022

The 45th annual San Antonio Breast Cancer Symposium. December 6 - 10, 2022
Breast Oncology Research Presentations Schedule Document

Breast Oncology Research Presentations Schedule

The 45th annual San Antonio Breast Cancer Symposium. December 6 - 10, 2022
Treatment Guidelines: Trastuzumab Deruxtecan (T-DXd) for Metastatic, HER2-low Breast Cancer Document

Treatment Guidelines: Trastuzumab Deruxtecan (T-DXd) for Metastatic, HER2-low Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on July 1 and July 8, 2022 to discuss recommendations for the use of trastuzumab deruxtecan (T-DXd) in patients with metastatic, HER2-low breast cancer.
Research Updates - Metastatic Breast Cancer Symposium

Research Updates - Metastatic Breast Cancer

In the following videos, faculty from Dana-Farber Cancer Institute review research updates from the 2022-2023 EMBRACE Metastatic Breast Cancer Patient Forum Series.
Study Finds Individuals With Inflammatory Breast Cancer at Higher Risk of Cancer Spread to the Brain News

Study Finds Individuals With Inflammatory Breast Cancer at Higher Risk of Cancer Spread to the Brain

New research from Dana-Farber Cancer Institute indicates that among individuals with breast cancer, those with a rare subtype called inflammatory breast cancer face a higher risk that their cancer will spread, or metastasize, to the brain.
Treatment Guidelines: Adjuvant Olaparib for BRCA1/2 Variant Carriers Document

Treatment Guidelines: Adjuvant Olaparib for BRCA1/2 Variant Carriers

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on May 6, May 20, June 1, and August 5, 2022 to discuss recommendations for the use of adjuvant olaparib for high-risk, breast cancer in BRCA1/2 carriers.
Research Update for ER-Positive MBC | 2022-2023 EMBRACE MBC Virtual Forum Series Video

Research Update for ER-Positive MBC | 2022-2023 EMBRACE MBC Virtual Forum Series

Filipa Lynce, MD; Nikhil Wagle, MD; and Lindsay Shaw, AOCNP, ACHPN, discuss advances in research and treatment for patients with ER-positive metastatic breast cancer.
Treatment Guidelines: Reflex Testing of OncotypeDX for Early Stage Breast Cancer Document

Treatment Guidelines: Reflex Testing of OncotypeDX for Early Stage Breast Cancer

The Breast Oncology Center held multidisciplinary meetings to discuss recommendations for updated criteria for reflex testing of OncotypeDX in patients with resected, hormone receptor positive, HER-2 negative, early breast cancer.

Showing 1 - 12 of 28 results

Previous| 1 | 2 | 3 |Next